12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VGX-100: Phase I started

Circadian began a dose-escalation, U.S. Phase I trial to evaluate VGX-100 as monotherapy and in combination with anti-angiogenic agents...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >